Ginell Post
Concepts (236)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 3 | 2019 | 50 | 1.120 |
Why?
| Plasma Cells | 4 | 2018 | 238 | 0.880 |
Why?
| Epidural Neoplasms | 1 | 2019 | 5 | 0.730 |
Why?
| ABO Blood-Group System | 1 | 2019 | 14 | 0.730 |
Why?
| Spinal Cord Compression | 1 | 2019 | 10 | 0.730 |
Why?
| von Willebrand Factor | 1 | 2019 | 54 | 0.710 |
Why?
| Pseudolymphoma | 1 | 2018 | 4 | 0.680 |
Why?
| Monocytes | 1 | 2019 | 156 | 0.680 |
Why?
| Scalp Dermatoses | 1 | 2018 | 8 | 0.680 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 3 | 2019 | 97 | 0.660 |
Why?
| Pulmonary Embolism | 1 | 2019 | 105 | 0.660 |
Why?
| Antigens, CD | 1 | 2019 | 242 | 0.650 |
Why?
| Tumor Microenvironment | 1 | 2019 | 207 | 0.650 |
Why?
| Hematologic Neoplasms | 1 | 2019 | 99 | 0.640 |
Why?
| Blood Coagulation Tests | 1 | 2017 | 24 | 0.640 |
Why?
| Optics and Photonics | 1 | 2017 | 13 | 0.630 |
Why?
| Endemic Diseases | 1 | 2017 | 29 | 0.630 |
Why?
| Diagnostic Tests, Routine | 1 | 2017 | 32 | 0.620 |
Why?
| Immunoglobulins | 1 | 2017 | 89 | 0.610 |
Why?
| Histoplasmosis | 1 | 2017 | 53 | 0.600 |
Why?
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.530 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2015 | 9 | 0.520 |
Why?
| Interleukin-6 | 1 | 2016 | 315 | 0.510 |
Why?
| Leukemoid Reaction | 1 | 2014 | 7 | 0.510 |
Why?
| Liposarcoma | 1 | 2014 | 24 | 0.510 |
Why?
| Antifungal Agents | 1 | 2017 | 363 | 0.500 |
Why?
| Muscle Neoplasms | 1 | 2014 | 21 | 0.500 |
Why?
| Neoplasms, Second Primary | 1 | 2014 | 77 | 0.480 |
Why?
| Sarcoma | 1 | 2014 | 73 | 0.470 |
Why?
| Neutrophils | 1 | 2014 | 156 | 0.470 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.440 |
Why?
| Fetomaternal Transfusion | 1 | 2012 | 3 | 0.440 |
Why?
| Plasma Exchange | 1 | 2012 | 33 | 0.430 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2012 | 27 | 0.420 |
Why?
| Cell Differentiation | 1 | 2015 | 717 | 0.410 |
Why?
| Liver | 1 | 2017 | 1246 | 0.390 |
Why?
| Humans | 27 | 2022 | 54132 | 0.390 |
Why?
| Graft vs Host Disease | 1 | 2011 | 82 | 0.380 |
Why?
| Myeloproliferative Disorders | 1 | 2010 | 28 | 0.370 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 277 | 0.360 |
Why?
| Bone Neoplasms | 1 | 2011 | 191 | 0.350 |
Why?
| Liver Transplantation | 1 | 2011 | 159 | 0.330 |
Why?
| Translocation, Genetic | 1 | 2010 | 286 | 0.330 |
Why?
| Multiple Myeloma | 4 | 2019 | 3024 | 0.330 |
Why?
| Phenotype | 2 | 2019 | 822 | 0.290 |
Why?
| Pancytopenia | 3 | 2011 | 40 | 0.280 |
Why?
| Receptors, Adrenergic, alpha-1 | 2 | 2003 | 12 | 0.270 |
Why?
| Immunohistochemistry | 3 | 2017 | 1097 | 0.260 |
Why?
| Lymphoma | 2 | 2018 | 62 | 0.250 |
Why?
| Male | 12 | 2022 | 27350 | 0.250 |
Why?
| Female | 11 | 2022 | 28437 | 0.240 |
Why?
| Lymph Nodes | 2 | 2016 | 282 | 0.230 |
Why?
| Peptide Hydrolases | 2 | 2014 | 67 | 0.230 |
Why?
| Macrophages | 2 | 2019 | 401 | 0.220 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1133 | 0.220 |
Why?
| Rad52 DNA Repair and Recombination Protein | 1 | 2022 | 3 | 0.220 |
Why?
| Immunoglobulin Class Switching | 1 | 2022 | 8 | 0.220 |
Why?
| Immunoglobulin D | 1 | 2022 | 4 | 0.220 |
Why?
| Enzyme Activators | 1 | 2002 | 8 | 0.210 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 18 | 0.210 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 168 | 0.210 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 78 | 0.210 |
Why?
| Biopsy | 2 | 2016 | 694 | 0.200 |
Why?
| Middle Aged | 5 | 2019 | 13094 | 0.200 |
Why?
| Tissue Array Analysis | 1 | 2019 | 50 | 0.180 |
Why?
| Paraffin Embedding | 1 | 2019 | 56 | 0.180 |
Why?
| Sarcoma, Myeloid | 1 | 2019 | 22 | 0.180 |
Why?
| Glycosylation | 1 | 2019 | 114 | 0.180 |
Why?
| Bacterial Proteins | 2 | 2014 | 455 | 0.170 |
Why?
| Adolescent | 3 | 2019 | 6890 | 0.170 |
Why?
| Aged, 80 and over | 2 | 2018 | 3442 | 0.170 |
Why?
| Color | 1 | 2018 | 29 | 0.160 |
Why?
| Automation | 1 | 2018 | 18 | 0.160 |
Why?
| Lymphatic Vessels | 1 | 2018 | 47 | 0.160 |
Why?
| Partial Thromboplastin Time | 1 | 2017 | 12 | 0.160 |
Why?
| Myocytes, Cardiac | 2 | 2013 | 136 | 0.160 |
Why?
| Prothrombin Time | 1 | 2017 | 19 | 0.160 |
Why?
| Immunophenotyping | 1 | 2018 | 117 | 0.160 |
Why?
| Failure to Thrive | 1 | 2017 | 21 | 0.160 |
Why?
| Histoplasma | 1 | 2017 | 29 | 0.160 |
Why?
| Clonal Evolution | 1 | 2018 | 60 | 0.160 |
Why?
| Rare Diseases | 1 | 2017 | 46 | 0.160 |
Why?
| Endothelial Cells | 1 | 2019 | 296 | 0.150 |
Why?
| Blood Coagulation | 1 | 2017 | 70 | 0.150 |
Why?
| Vomiting | 1 | 2017 | 73 | 0.150 |
Why?
| Biopsy, Needle | 1 | 2017 | 195 | 0.150 |
Why?
| Young Adult | 2 | 2019 | 4320 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 206 | 0.140 |
Why?
| Neoplasm, Residual | 1 | 2017 | 167 | 0.140 |
Why?
| Lung | 1 | 2019 | 512 | 0.140 |
Why?
| Bone Marrow | 1 | 2018 | 415 | 0.140 |
Why?
| Risk Assessment | 2 | 2017 | 1363 | 0.140 |
Why?
| Algorithms | 1 | 2019 | 697 | 0.130 |
Why?
| Weight Loss | 1 | 2017 | 271 | 0.130 |
Why?
| V(D)J Recombination | 1 | 2015 | 4 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 548 | 0.130 |
Why?
| Pyridines | 2 | 2008 | 137 | 0.120 |
Why?
| Fatal Outcome | 1 | 2014 | 225 | 0.120 |
Why?
| Neoplasm Metastasis | 2 | 2012 | 252 | 0.120 |
Why?
| Protein Kinases | 1 | 2014 | 88 | 0.120 |
Why?
| Aged | 3 | 2019 | 10059 | 0.120 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 88 | 0.110 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 533 | 0.110 |
Why?
| Transcription Factors | 2 | 2014 | 619 | 0.110 |
Why?
| Rh Isoimmunization | 1 | 2012 | 2 | 0.110 |
Why?
| Rho(D) Immune Globulin | 1 | 2012 | 3 | 0.110 |
Why?
| Chromogranins | 1 | 2012 | 5 | 0.110 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2012 | 14 | 0.110 |
Why?
| Synaptophysin | 1 | 2012 | 9 | 0.110 |
Why?
| Vimentin | 1 | 2012 | 33 | 0.110 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 165 | 0.100 |
Why?
| Follow-Up Studies | 1 | 2017 | 2384 | 0.100 |
Why?
| Virulence Factors | 1 | 2012 | 92 | 0.100 |
Why?
| Leukemia, Myelomonocytic, Chronic | 1 | 2011 | 17 | 0.100 |
Why?
| Leukocytosis | 1 | 2011 | 14 | 0.100 |
Why?
| Antineoplastic Agents | 2 | 2012 | 1295 | 0.100 |
Why?
| Chimerism | 1 | 2011 | 8 | 0.100 |
Why?
| Plateletpheresis | 1 | 2010 | 8 | 0.100 |
Why?
| Telomerase | 1 | 2010 | 30 | 0.100 |
Why?
| Blood Preservation | 1 | 2010 | 29 | 0.100 |
Why?
| Myelodysplastic Syndromes | 1 | 2011 | 79 | 0.100 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2010 | 17 | 0.100 |
Why?
| Infant | 2 | 2017 | 3797 | 0.100 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2010 | 20 | 0.100 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2010 | 20 | 0.100 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 244 | 0.090 |
Why?
| Adult | 3 | 2019 | 14196 | 0.090 |
Why?
| Keratinocytes | 1 | 2011 | 96 | 0.090 |
Why?
| Blood Proteins | 1 | 2010 | 101 | 0.090 |
Why?
| Retrospective Studies | 2 | 2019 | 6387 | 0.090 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2011 | 115 | 0.090 |
Why?
| Bone Marrow Cells | 1 | 2011 | 234 | 0.090 |
Why?
| Neural Tube Defects | 1 | 2008 | 29 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2012 | 361 | 0.080 |
Why?
| Thoracic Wall | 1 | 2008 | 9 | 0.080 |
Why?
| Copper | 1 | 2008 | 48 | 0.080 |
Why?
| Benzenesulfonates | 1 | 2008 | 13 | 0.080 |
Why?
| Mice | 6 | 2022 | 6436 | 0.080 |
Why?
| Nerve Sheath Neoplasms | 1 | 2008 | 23 | 0.080 |
Why?
| Neurilemmoma | 1 | 2008 | 27 | 0.080 |
Why?
| Treatment Outcome | 2 | 2017 | 5596 | 0.080 |
Why?
| Blood Platelets | 1 | 2010 | 269 | 0.080 |
Why?
| Animals | 8 | 2022 | 14435 | 0.080 |
Why?
| Cells, Cultured | 3 | 2013 | 1755 | 0.080 |
Why?
| Atherosclerosis | 1 | 2010 | 253 | 0.080 |
Why?
| Skin | 1 | 2011 | 469 | 0.070 |
Why?
| Mice, Knockout | 3 | 2022 | 941 | 0.070 |
Why?
| Inflammation | 1 | 2010 | 677 | 0.070 |
Why?
| Isoenzymes | 2 | 2003 | 180 | 0.060 |
Why?
| Pregnancy | 1 | 2012 | 2614 | 0.060 |
Why?
| Infant, Newborn | 1 | 2012 | 2901 | 0.060 |
Why?
| Uridine Triphosphate | 1 | 2003 | 13 | 0.060 |
Why?
| Heart | 2 | 2003 | 364 | 0.060 |
Why?
| Catheter-Related Infections | 2 | 2014 | 55 | 0.060 |
Why?
| Chromosome Aberrations | 2 | 2018 | 315 | 0.060 |
Why?
| Virulence | 2 | 2014 | 194 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2014 | 1645 | 0.050 |
Why?
| Adrenergic alpha-1 Receptor Agonists | 1 | 2002 | 3 | 0.050 |
Why?
| Thymidine | 1 | 2002 | 19 | 0.050 |
Why?
| Bacteremia | 2 | 2014 | 102 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 38 | 0.050 |
Why?
| MAP Kinase Kinase 4 | 1 | 2002 | 34 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2022 | 65 | 0.050 |
Why?
| Gene Knockdown Techniques | 1 | 2022 | 127 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2003 | 253 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 99 | 0.050 |
Why?
| Recombination, Genetic | 1 | 2022 | 108 | 0.050 |
Why?
| Enzyme Activation | 1 | 2002 | 333 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2022 | 176 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 330 | 0.050 |
Why?
| Imidazoles | 1 | 2002 | 143 | 0.050 |
Why?
| Methionine | 1 | 2002 | 147 | 0.050 |
Why?
| Blotting, Western | 1 | 2002 | 685 | 0.050 |
Why?
| Phosphorylation | 1 | 2022 | 609 | 0.050 |
Why?
| Myocardium | 1 | 2003 | 445 | 0.050 |
Why?
| Carrier Proteins | 1 | 2002 | 360 | 0.050 |
Why?
| Fibroblasts | 1 | 2002 | 386 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2022 | 463 | 0.040 |
Why?
| Rats | 2 | 2003 | 3435 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2018 | 24 | 0.040 |
Why?
| DNA | 1 | 2002 | 582 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2013 | 662 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 200 | 0.040 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2013 | 17 | 0.030 |
Why?
| Animals, Outbred Strains | 1 | 2012 | 13 | 0.030 |
Why?
| Daptomycin | 1 | 2012 | 33 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 289 | 0.030 |
Why?
| Prognosis | 1 | 2017 | 2116 | 0.030 |
Why?
| Cell Survival | 1 | 2013 | 661 | 0.030 |
Why?
| Karyotyping | 1 | 2011 | 93 | 0.020 |
Why?
| Isotonic Solutions | 1 | 2010 | 21 | 0.020 |
Why?
| P-Selectin | 1 | 2010 | 33 | 0.020 |
Why?
| Platelet Transfusion | 1 | 2010 | 32 | 0.020 |
Why?
| Biofilms | 1 | 2012 | 200 | 0.020 |
Why?
| Receptors, LDL | 1 | 2010 | 70 | 0.020 |
Why?
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 13 | 0.020 |
Why?
| Platelet Aggregation | 1 | 2010 | 82 | 0.020 |
Why?
| Platelet Activation | 1 | 2010 | 49 | 0.020 |
Why?
| Sodium Chloride | 1 | 2010 | 67 | 0.020 |
Why?
| Time Factors | 1 | 2017 | 3223 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2010 | 199 | 0.020 |
Why?
| Hypersensitivity | 1 | 2010 | 82 | 0.020 |
Why?
| Staphylococcal Infections | 1 | 2012 | 300 | 0.020 |
Why?
| Short Bowel Syndrome | 1 | 2008 | 15 | 0.020 |
Why?
| Parenteral Nutrition, Total | 1 | 2008 | 26 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2010 | 195 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 336 | 0.020 |
Why?
| Coronary Vessels | 1 | 2010 | 197 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2008 | 16 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 436 | 0.020 |
Why?
| Niacinamide | 1 | 2008 | 25 | 0.020 |
Why?
| Enterocolitis, Necrotizing | 1 | 2008 | 36 | 0.020 |
Why?
| Radiography, Thoracic | 1 | 2008 | 70 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2008 | 216 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 816 | 0.020 |
Why?
| Brain Neoplasms | 1 | 2008 | 284 | 0.020 |
Why?
| Mutation | 1 | 2011 | 1499 | 0.020 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| Purinergic P2 Receptor Antagonists | 1 | 2003 | 4 | 0.010 |
Why?
| Phospholipase C gamma | 1 | 2003 | 4 | 0.010 |
Why?
| Adrenergic Agonists | 1 | 2003 | 7 | 0.010 |
Why?
| Phospholipase C beta | 1 | 2003 | 2 | 0.010 |
Why?
| Type C Phospholipases | 1 | 2003 | 16 | 0.010 |
Why?
| Phenylephrine | 1 | 2003 | 34 | 0.010 |
Why?
| Perfusion | 1 | 2003 | 40 | 0.010 |
Why?
| Hypertrophy | 1 | 2003 | 52 | 0.010 |
Why?
| Vasoconstriction | 1 | 2003 | 60 | 0.010 |
Why?
| Cyclic AMP | 1 | 2003 | 114 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2008 | 631 | 0.010 |
Why?
| Aorta | 1 | 2003 | 182 | 0.010 |
Why?
| Animals, Newborn | 1 | 2003 | 397 | 0.010 |
Why?
| Electrocardiography | 1 | 2003 | 286 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2008 | 1603 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2003 | 1478 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2003 | 1676 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|